The results of this trial, in conjunction with our results using LCTB-92 in a preclinical animal model of MI, are encouraging in that the inhibition of DYRK1A may represent a new first-in-class therapy to treat heart disease. The gene discussed is DYRK1A; the disease is heart disorder.